1. Business Update Conference Call
May 19, 2016

2. Forward-Looking Statements
Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Any forward-looking statements contained herein or made in the course of the presentation are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC and the British Columbia Securities Commission, including our current reports on Form 8-K’s, Form 10-Q’s and most recent Form 10-K. We do not undertake to update these forward-looking statements made by us.

3. DelMar Pharmaceuticals, Inc
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) 2016: A Transformational Year
Recent Highlights
FINRA approved 1:4 reverse stock split in preparation for senior exchange up-listing
$6.1 million private placement
Restructured 72% of outstanding investor warrants to reduce derivative liability
Presented three abstracts at American Association for Cancer Research Annual Meeting
US FDA expanded orphan designation for VAL-083 to include medulloblastoma and ovarian cancer
MD Anderson Collaboration for first-recurrence of GBM

4. Selected Statement of Operations Data for the three months ended:
Current operating funds thru end of 2017
Quarterly Burn: ~$1 million
Cash available from “in the money” warrants: $10 million
Net Equity and operating funds sufficient to meet senior exchange requirements
$000
March 31, 2016
March 31, 2015
(as restated)
Research & Development $ $
General & Administrative
630
501
Change in fair value of derivative liability
(269)
781
Loss on exchange of warrants --
156
Foreign exchange (gain) loss
(11) 7
Net loss from operations
$ 1,140
$ 2,087
Basic loss per share
$0.03
$0.05

5. DelMar Pharmaceuticals Financial Snapshot
Current operating funds thru end of 2017
Quarterly Burn: ~$1 million
Cash available from “in the money” warrants: $10 million
Net Equity and operating funds sufficient to meet senior exchange requirements
31-Mar/2016
Pro-Forma
Cash
$937K
$6.4 m
Derivative Liability
$1.0 m
$500K
Net Shareholders Equity/(Deficit)
$(687K)
$5.3 m
Common Shares Outstanding
Pre-split
Post-split
DMPI Shares
40.2 m
10.0 m
ExchangeCo
4.0 m
1.0 m
Total Outstanding
44.2 m
11.0 m
Other securities (as converted to common)
Preferred Shares
7.6m
1.9 m
Warrants
18.4 m
18.7m
4.7 m
Options
3.5 m
3.4m
0.9 m
Fully Diluted
66.1 m
73.9 m
18.5 m

6. Select Senior Exchange Listing Requirements
DelMar current net equity and operating funds sufficient to meet senior exchange requirements
LISTING STANDARD
NYSE-MKT
NASDAQ
Standard #2
Standard #3
Equity Standard
Market Value Standard
Stockholders Equity
$4 million
$ 4 million
$ 5 million
Market Cap
n.a.
$50 million
Round Lot Holders
400
300
Minimum Bid Price $3 $2 $4

7. VAL-083: DelMar’s Initial Product Candidate
Historical data from NCI-sponsored research
First-in-class small molecule chemotherapy
>40 NCI-sponsored clinical trials demonstrate clinical activity against multiple tumor types
CNS, Solid & Hematologic Tumors
Readily crosses blood-brain-barrier
Safety database: >1000 patients
Safety & toxicity
Pharmacokinetics
C6H10O MW=146

8. SOLVE UNMET NEEDS IN CANCER TREATMENT TODAY
VAL-083: DelMar’s Initial Product Candidate Leveraging Historical Clinical Data with Modern Science
Reduce Cost, Risk & Time in Drug Discovery & Development
SOLVE UNMET NEEDS
IN CANCER TREATMENT
TODAY
VAL-083
PRIOR
CLINICAL VALIDATION
> 40 NCI-sponsored clinical trials
Ex-USA clinical research
Modern Understanding of
Biological Mechanism
New
I.P.

9. AACR 2016: VAL-083 Mechanism of Action
s-phase arrest

10. AACR 2016: VAL-083 Mechanism of Action
VAL-083 takes advantage of defects in cellular machinery that is common to cancer cells
VAL-083 rapidly forms DNA cross links at N7-position of guanine
Cancer cells are defective in DNA damage checkpoints
Cross-link is durable and difficult for cancer cells to repair
Cancer cells are defective in homologous repair mechanism
Cell cycle arrest and cancer cell death in S-phase during DNA replication
Active independent of common chemo-resistance mechanisms (e.g. MGMT, MMR, p53)
Resistance to VAL-083 treatment is difficult for cancer cells to acquire

11. VAL-083 Targeting Unmet Medical Needs in Cancer
VAL-083 Mechanism:
Differentiation from Standard-of-Care Chemotherapy = Commercial Opportunity in Solving Unmet Medical Needs
Chemotherapy = standard of care
VAL-083 historical clinical activity
chemo resistance = unmet medical need

12. VAL-083 Targeting Unmet Medical Needs in Cancer
Data supports VAL-083 for multiple cancer indications
2014 ww Revenue
Non-small cell lung cancer
$6.8 B
Glioma
$1.0 B
Ovarian cancer
>$500 M
Pediatric medulloblastoma
orphan
Source: Evaluate Pharma

13. VAL-083’s First Opportunity: A Paradigm Shift in the Treatment of GBM
VAL-083 Addresses MGMT-mediated resistance: A Major Unmet Need
2/3 of newly diagnosed GBM patients are resistant to Temodar® due to high-expression of MGMT
VAL-083 is active independent of MGMT-resistance
MGMT is a biomarker for patient selection
Prior NCI-sponsored trials demonstrate clinical activity against GBM

14. VAL-083 Post Avastin Refractory GBM Ongoing Phase I/II Clinical Trial
AACR 2016
Ongoing Phase I/II Clinical Trial in Post-Avastin GBM
Defined well-tolerated dosing regimen with good therapeutic window
Treating “most difficult” GBM patients (high MGMT + IDH1wt )
Observed clinical activity (survival benefit) supported by pharmacokinetic data
Next Steps:
Meeting with USFDA to discuss planned Phase III Clinical Trial in Post-Avastin GBM
Two New Phase II Clinical Trials in GBM Patients with High MGMT
Newly Diagnosed
First Recurrence
Phase I/II: Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
Patients have failed Temodar® (temozolomide) and Avastin® (bevacizumab)
ClinicalTrials.gov Identifier: NCT

15. VAL-083 Post Avastin Refractory GBM Ongoing Phase I/II Clinical Trial
We have determined a dosing regimen suitable for advancement to registration-directed trials
40 mg/m2/daily every 3 days in a 21 day cycle has been selected for advancement
Dose limiting toxicities (DLT) observed at doses above 40 mg/m2
DLT primarily thrombocytopenia, resolves rapidly and spontaneously following treatment
No DLT observed below 40 mg/m2
One DLT due to prior drug exposure observed at 40 mg/m2
Addressed via enrollment criteria requiring higher platelets for patients with prior nitrosourea

16. VAL-083 Post Avastin Refractory GBM Ongoing Phase I/II Clinical Trial
Assess Patient Outcomes:
Data suggests survival signal superior to historical literature in Avastin-failed GBM patients
Pharmacokinetics support activity
Reference
Post Avastin Salvage Therapy
Median Survival from
Avastin Failure
Rahman (2014)
nitrosourea
4.3 months
Mikkelson (2011)
TMZ + irinotecan
4.5 months
Lu (2011)
dasatinib
2.6 months
Reardon (2011)
etoposide
4.7 months
TMZ
2.9 months
Iwomoto (2009)
various
5.1 months
VAL-083 interim
Therapeutic Dose After Avastin Failure
6 months
9 months
12 months
52%
43%
22%
Expected Median OS: 8 – 9 months
40 mg/m2/d
Estimated Maximum Tumor Concentration in Brain (day 3)
IC50 in
GBM Cell Lines
3.86 μM
2 – 4 μM

17. VAL-083 Post Avastin Refractory GBM Ongoing Phase I/II Clinical Trial
Important factor
Majority of GBM tumors tested for biomarkers in VAL-083 trial exhibited features associated with particularly poor outcomes
High expression of MGMT: 84%
IDH1wt : 91%
Impact of MGMT and IDH1 on Survival (published studies)
MGMT Expression
mOS
Low
23 months
High
16 months
Gilbert et al, JCO 2013
Isocitrate dehyrogenase (IDH1)
mOS
IDH mutant
>60 months
IDH1 wild-type
~18 months
Combs et al., Rad Onc 2011
Time (months)
100-
80-
60-
40-
20-
Overall Survival (%) 12 24 36 48
MGMT Promoter (expression)
Methylated (low)
Unmethylated (high)
IDH1MUT
IDH1WT
100-
80-
60-
40-
20- 11
Overall Survival (%) 10 20 30 40 50 60 80 90
Time (months)

18. VAL-083’s First Opportunity: GBM 2016 Clinical Plan … Implementing the Paradigm Shift
Current Treatment Paradigm
New Paradigm Vision
for VAL-083
Diagnosis
Diagnosis
Surgical “debulking”
Surgical “debulking”
Temodar® + Radiation
MGMT Assessment
2/3 of patients fail
HIGH MGMT
(unmethylated)
LOW MGMT
(methylated)
Avastin®
2/3
VAL-083 +
Radiotherapy
1/3
Temodar® +
Radiotherapy
No impact on survival
VAL-083
Phase II/III Clinical Trial Refractory GBM
Planed H2-2016
Describe paradigm shift for 2/3 of patients
China Clinical Trial
to begin
H1-2016
USA-MDACC Clinical Trial
to begin
H1-2016
Newly Diagnosed GBM
VAL-083 +
Radiotherapy
First GBM Recurrence following temozolomide failure
MDACC: MD Anderson Cancer Center

19. VAL-083’s First Opportunity: GBM
VAL-083’s distinct anti-cancer mechanism
Would create a new survival paradigm for the first time in decades
Unlocks potential to overcome chemo-resistance and surpass standard of care
Lays the foundation for global development to address >$1 billion market opportunity as chemotherapy of choice in the treatment of GBM

20. Expanding DelMar’s VAL-083 Portfolio
VAL-083 Mechanism:
Differentiation from Standard-of-Care Chemotherapy = Commercial Opportunity in Solving Unmet Medical Needs
Glioblastoma Multiforme
Non-small cell lung cancer
Ovarian Cancer
CNS metastases
Combination chemotherapy
Pediatric brain tumors
Chemotherapy = standard of care
VAL-083 historical clinical activity
VAL-083 unique mechanism to overcome chemo- resistance

21. China – Partnered with Manufacturer
DelMar Pharma 2016: A Transformational Year
PROFORMA: H NYSE/NASDAQ: DMPI
VAL-083
Phase I
Phase II
Phase III
NDA /
COMMERCIAL
STATUS: May 2016
GBM: Post-Avastin
FDA End of Phase 2 meeting H1-2016
GBM: First-recurrence (MDACC)
Two new GBM Trials: IRB/Ethics Committee Submissions Underway
GBM: Newly Diagnosed MGMT+
Non-small cell lung cancer
Protocol update based on mechanism
Ovarian
Pre-clinical research into combination therapies
Pediatric
CNS Tumors
Pre-clinical research and discussions with KoLs regarding clinical protocol design
Grant
supported
research
Potential to expand pipeline in additional indications
China – Partnered with Manufacturer
Lung Cancer – CFDA Approved
CML – CFDA Approved

22. Growing Patent Portfolio: Robust Intellectual Property Protection
Eight separate patent families with multiple patents
Claims include use, manufacturing, analytical, mechanism and composition claims
Five US patents and four international patents issued to date
Patent protection into 2033 in USA
90 additional patents + 4 provisional applications pending
VAL-083 granted orphan drug designation in US & EU
Seven years market exclusivity after approval in US
10 years market exclusivity after approval in Europe

23. 2016: Actionable Milestones
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) 2016: A Transformational Year
2016: Actionable Milestones
Clinical Research
Refractory GBM
Advancing to Phase III
Front-line GBM
New Phase II clinical trial planned
First Recurrence in GBM
New Phase II clinical trial planned (collaboration with MDACC)
Non-small cell lung cancer
Pre-clinical Research
Ovarian Cancer
Pre-clinical research to define clinical strategy
Medulloblastoma
Combination Therapies
Pre-clinical research underway
Regulatory
FDA Guidance Meeting in preparation for Phase III clinical trials in refractory GBM
Corporate
National Exchange Listing (NYSE-MKT or NASDAQ)

24. DelMar Pharmaceuticals Investment Opportunity
VAL-083
“First‐in‐class" small molecule chemotherapy
Unique anti-cancer mechanism overcomes chemo-resistance
NCI demonstrated clinical activity across a range of cancers
Promising interim outcomes data in refractory GBM clinical trial
Advancing to “late-stage” clinical development in 2016
Pipeline expansion opportunities in high value oncology markets
Robust IP protection from newly issued patents
Orphan drug designation in USA and EU
Experienced Team with History of Success
Solid Financial Position
Transformational Near-term Catalysts